Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Selected Articles from This Issue
    Mol Cancer Ther February 1 2021 20 (2) 217-217;

Reviews

  • Reviews
    Targeting STAT3 with Proteolysis Targeting Chimeras and Next-Generation Antisense Oligonucleotides
    Jamie V. Shiah, Jennifer R. Grandis and Daniel E. Johnson
    Mol Cancer Ther February 1 2021 20 (2) 219-228; DOI:10.1158/1535-7163.MCT-20-0599

  • Reviews
    Therapeutic Vulnerabilities of Transcription Factors in AML
    Irum Khan, Elizabeth E. Eklund and Andrei L. Gartel
    Mol Cancer Ther February 1 2021 20 (2) 229-237; DOI:10.1158/1535-7163.MCT-20-0115

Small Molecule Therapeutics

  • Small Molecule Therapeutics | AuthorChoice
    AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
    Vikki Flemington, Emma J. Davies, David Robinson, Linda C. Sandin, Oona Delpuech, Pei Zhang, Lyndsey Hanson, Paul Farrington, Sigourney Bell, Katarzyna Falenta, Francis D. Gibbons, Nicola Lindsay, Aaron Smith, Joanne Wilson, Karen Roberts, Michael Tonge, Philip Hopcroft, Sophie E. Willis, Martine P. Roudier, Claire Rooney, Elizabeth A. Coker, Patricia Jaaks, Mathew J. Garnett, Stephen E. Fawell, Clifford D. Jones, Richard A. Ward, Iain Simpson, Sabina C. Cosulich, J. Elizabeth Pease and Paul D. Smith
    Mol Cancer Ther February 1 2021 20 (2) 238-249; DOI:10.1158/1535-7163.MCT-20-0002

  • Small Molecule Therapeutics | AuthorChoice
    SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
    Maysoun Shomali, Jane Cheng, Fangxian Sun, Malvika Koundinya, Zhuyan Guo, Andrew T. Hebert, Jessica McManus, Mikhail N. Levit, Dietmar Hoffmann, Albane Courjaud, Rosalia Arrebola, Hui Cao, Jack Pollard, Joon Sang Lee, Laurent Besret, Anne Caron, Dinesh S. Bangari, Pierre-Yves Abecassis, Laurent Schio, Youssef El-Ahmad, Frank Halley, Michel Tabart, Victor Certal, Fabienne Thompson, Gary McCort, Bruno Filoche-Rommé, Hong Cheng, Carlos Garcia-Echeverria, Laurent Debussche and Monsif Bouaboula
    Mol Cancer Ther February 1 2021 20 (2) 250-262; DOI:10.1158/1535-7163.MCT-20-0390

  • Small Molecule Therapeutics
    Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic Cancer
    Leslie A. Parsels, Carl G. Engelke, Joshua Parsels, Sheryl A. Flanagan, Qiang Zhang, Daria Tanska, Daniel R. Wahl, Christine E. Canman, Theodore S. Lawrence and Meredith A. Morgan
    Mol Cancer Ther February 1 2021 20 (2) 263-273; DOI:10.1158/1535-7163.MCT-20-0365

  • Small Molecule Therapeutics
    Leflunomide Suppresses the Growth of LKB1-Inactivated Tumors in the Immune-Competent Host and Attenuates Distant Cancer Metastasis
    Rui Jin, Boxuan Liu, Xiuju Liu, Yijian Fan, Wei Peng, Chunzi Huang, Adam Marcus, Gabriel Sica, Melissa Gilbert-Ross, Yuan Liu and Wei Zhou
    Mol Cancer Ther February 1 2021 20 (2) 274-283; DOI:10.1158/1535-7163.MCT-20-0567

  • Small Molecule Therapeutics | AuthorChoice
    Inhibition of Intermedin (Adrenomedullin 2) Suppresses the Growth of Glioblastoma and Increases the Antitumor Activity of Temozolomide
    Luping Huang, Denian Wang, Zhongxue Feng, Huan Zhao, Fei Xiao, Yong'gang Wei, Heng Zhang, Hongyu Li, Lingmiao Kong, Min Li, Fei Liu, Haili Zhang and Wei Zhang
    Mol Cancer Ther February 1 2021 20 (2) 284-295; DOI:10.1158/1535-7163.MCT-20-0619

  • Small Molecule Therapeutics
    Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway–Dependent Apoptosis
    Xuemei Xie, Jangsoon Lee, Huey Liu, Troy Pearson, Alexander Y. Lu, Debu Tripathy, Gayathri R. Devi, Chandra Bartholomeusz and Naoto T. Ueno
    Mol Cancer Ther February 1 2021 20 (2) 296-306; DOI:10.1158/1535-7163.MCT-19-1160

  • Small Molecule Therapeutics | AuthorChoice
    Rigosertib Induces Mitotic Arrest and Apoptosis in RAS-Mutated Rhabdomyosarcoma and Neuroblastoma
    Joshua T. Kowalczyk, Xiaolin Wan, Edjay R. Hernandez, Ruibai Luo, Gaelyn C. Lyons, Kelli M. Wilson, Devorah C. Gallardo, Kristine A. Isanogle, Christina M. Robinson, Arnulfo Mendoza, Christine M. Heske, Jinqui-Qiu Chen, Xiaoling Luo, Alexander E. Kelly, Simone Difilippantinio, Robert W. Robey, Craig J. Thomas, Dan L. Sackett, Deborah K. Morrison, Paul A. Randazzo, Lisa M. Miller Jenkins and Marielle E. Yohe
    Mol Cancer Ther February 1 2021 20 (2) 307-319; DOI:10.1158/1535-7163.MCT-20-0525

Large Molecule Therapeutics

  • Large Molecule Therapeutics
    Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models
    Philip N. Moquist, Tim D. Bovee, Andrew B. Waight, Jamie A. Mitchell, Jamie B. Miyamoto, Marsha L. Mason, Kim K. Emmerton, Nicole Stevens, Cindy Balasubramanian, Jessica K. Simmons, Robert P. Lyon, Peter D. Senter and Svetlana O. Doronina
    Mol Cancer Ther February 1 2021 20 (2) 320-328; DOI:10.1158/1535-7163.MCT-20-0618

  • Large Molecule Therapeutics
    Development of Novel Antibody–Camptothecin Conjugates
    Ryan D. Lyski, Lauren B. Bou, Uland Y. Lau, David W. Meyer, Julia H. Cochran, Nicole M. Okeley, Kim K. Emmerton, Francisco Zapata, Jessica K. Simmons, Esther S. Trueblood, David J. Ortiz, Margo C. Zaval, Katie M. Snead, Steven Jin, Lauren M. Farr, Maureen C. Ryan, Peter D. Senter and Scott C. Jeffrey
    Mol Cancer Ther February 1 2021 20 (2) 329-339; DOI:10.1158/1535-7163.MCT-20-0526

  • Large Molecule Therapeutics
    An Anti–CD22-seco-CBI-Dimer Antibody–Drug Conjugate (ADC) for the Treatment of Non-Hodgkin Lymphoma That Provides a Longer Duration of Response than Auristatin-Based ADCs in Preclinical Models
    Shang-Fan Yu, Donna W. Lee, Bing Zheng, Geoffrey del Rosario, Douglas Leipold, Helen Booler, Fiona Zhong, Montserrat Carrasco-Triguero, Kyu Hong, Peter Yan, Rebecca K. Rowntree, Melissa M. Schutten, Thomas Pillow, Jack D. Sadowsky, Peter S. Dragovich and Andrew G. Polson
    Mol Cancer Ther February 1 2021 20 (2) 340-346; DOI:10.1158/1535-7163.MCT-20-0046

  • Large Molecule Therapeutics | AuthorChoice
    Single-Dose Anti–PD-L1/IL-15 Fusion Protein KD033 Generates Synergistic Antitumor Immunity with Robust Tumor-Immune Gene Signatures and Memory Responses
    Stella A. Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Zhikai Zhang, Sam Feldstein, Radovan Lumban-Tobing, Danielle K. Almstead, Faical Miyara and Jeegar Patel
    Mol Cancer Ther February 1 2021 20 (2) 347-356; DOI:10.1158/1535-7163.MCT-20-0457

  • Large Molecule Therapeutics
    Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining In Vitro Experiments with Systems Modeling
    Arthur J. Van De Vyver, Tina Weinzierl, Miro J. Eigenmann, Nicolas Frances, Sylvia Herter, Regula B. Buser, Jitka Somandin, Sarah Diggelmann, Florian Limani, Thorsten Lehr, Marina Bacac and Antje-Christine Walz
    Mol Cancer Ther February 1 2021 20 (2) 357-366; DOI:10.1158/1535-7163.MCT-20-0269

  • Large Molecule Therapeutics
    HDP-101, an Anti-BCMA Antibody–Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells
    Vianihuini Figueroa-Vazquez, Jonathan Ko, Christian Breunig, Anja Baumann, Nicola Giesen, Anikó Pálfi, Christoph Müller, Christian Lutz, Torsten Hechler, Michael Kulke, Carsten Müller-Tidow, Alwin Krämer, Hartmut Goldschmidt, Andreas Pahl and Marc S. Raab
    Mol Cancer Ther February 1 2021 20 (2) 367-378; DOI:10.1158/1535-7163.MCT-20-0287

Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers

  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
    BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma
    Sara Busacca, Laura O'Regan, Anita Singh, Annabel J. Sharkey, Alan G. Dawson, Joanna Dzialo, Aimee Parsons, Neelam Kumar, Laurel M. Schunselaar, Naomi Guppy, Apostolos Nakas, Michael Sheaff, Aaron S. Mansfield, Sam M. Janes, Paul Baas, Andrew M. Fry and Dean A. Fennell
    Mol Cancer Ther February 1 2021 20 (2) 379-388; DOI:10.1158/1535-7163.MCT-20-0363

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma
    Kim A. Reiss, Max M. Wattenberg, Nevena Damjanov, Elizabeth Prechtel Dunphy, Mona Jacobs-Small, M. Judy Lubas, James Robinson, Lisa Dicicco, Luis Garcia-Marcano, Michael A. Giannone, Thomas B. Karasic, Emma E. Furth, Erica L. Carpenter, Andrzej P. Wojcieszynski, Robert H. Vonderheide, Gregory L. Beatty and Edgar Ben-Josef
    Mol Cancer Ther February 1 2021 20 (2) 389-397; DOI:10.1158/1535-7163.MCT-20-0632

  • Cancer Biology and Translational Studies
    Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells In Vitro
    Sarah E. Kohrt, Wisam N. Awadallah, Robert A. Phillips III, Thomas C. Case, Renjie Jin, Jagpreet S. Nanda, Xiuping Yu, Peter E. Clark, Yajun Yi, Robert J. Matusik, Philip D. Anderson and Magdalena M. Grabowska
    Mol Cancer Ther February 1 2021 20 (2) 398-409; DOI:10.1158/1535-7163.MCT-20-0244

  • Cancer Biology and Translational Studies
    EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1
    Brenna Weadick, Debasis Nayak, Avinash K. Persaud, Sau Wai Hung, Radhika Raj, Moray J. Campbell, Wei Chen, Junan Li, Terence M. Williams and Rajgopal Govindarajan
    Mol Cancer Ther February 1 2021 20 (2) 410-422; DOI:10.1158/1535-7163.MCT-20-0316

Models and Technologies

  • Models and Technologies
    The HPV and p63 Status in Penile Cancer Are Linked with the Infiltration and Therapeutic Availability of Neutrophils
    Muriel Charlotte Bernhard, Anabel Zwick, Tobias Mohr, Gilles Gasparoni, Oybek Khalmurzaev, Vsevolod Borisovich Matveev, Philine Loertzer, Alexey Pryalukhin, Arndt Hartmann, Carol-Immanuel Geppert, Hagen Loertzer, Heiko Wunderlich, Carsten Maik Naumann, Holger Kalthoff, Kerstin Junker, Sigrun Smola and Stefan Lohse
    Mol Cancer Ther February 1 2021 20 (2) 423-437; DOI:10.1158/1535-7163.MCT-20-0173

  • Models and Technologies
    Cabozantinib Unlocks Efficient In Vivo Targeted Delivery of Neutrophil-Loaded Nanoparticles into Murine Prostate Tumors
    Kiranj Kishor Chaudagar, Natalie Landon-Brace, Aniruddh Solanki, Hanna M. Hieromnimon, Emma Hegermiller, Wen Li, Yue Shao, John Joseph, Devan J. Wilkins, Kaela M. Bynoe, Xiang-Ling Li, John G. Clohessy, Soumya Ullas, Jeffrey M. Karp and Akash Patnaik
    Mol Cancer Ther February 1 2021 20 (2) 438-449; DOI:10.1158/1535-7163.MCT-20-0167

Corrections

  • Corrections | Free Article
    Correction: Combined Inhibition of NEDD8-activating Enzyme and mTOR Suppresses NF2 Loss–driven Tumorigenesis
    Jonathan Cooper, Qingwen Xu, Lu Zhou, Milica Pavlovic, Virginia Ojeda, Kamalika Moulick, Elisa de Stanchina, John T. Poirier, Marjorie Zauderer, Charles M. Rudin, Matthias A. Karajannis, C. Oliver Hanemann and Filippo G. Giancotti
    Mol Cancer Ther February 1 2021 20 (2) 450-450; DOI:10.1158/1535-7163.MCT-20-1027

  • Corrections | Free Article
    Correction: MALAT1 is Associated with Poor Response to Oxaliplatin-based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2
    Peilong Li, Xin Zhang, Haiyan Wang, Lili Wang, Tong Liu, Lutao Du, Yongmei Yang and Chuanxin Wang
    Mol Cancer Ther February 1 2021 20 (2) 451-451; DOI:10.1158/1535-7163.MCT-20-1028

Back to top
PreviousNext
Molecular Cancer Therapeutics: 20 (2)
February 2021
Volume 20, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS-Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib
  • Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination–Proficient Pancreatic Cancer
  • Novel Auristatins with High Bystander and Cytotoxic Activities in Drug Efflux–positive Tumor Models
  • A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma

Jump to

  • Highlights
  • Reviews
  • Small Molecule Therapeutics
  • Large Molecule Therapeutics
  • Companion Diagnostic, Pharmacogenomic, and Cancer Biomarkers
  • Cancer Biology and Translational Studies
  • Models and Technologies
  • Corrections
Advertisement
  • Most Cited
  • Most Read
Loading
  • Anti-KIT DNA Aptamer Labeling in GIST
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Tipifarnib as a Precision Therapy for HRAS-Mutant HNSCC
  • Targeted Delivery of MMAE Using Bicycle Molecules
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement